Lower drug sales potential at Bayer underscores need for deals
2018-12-5 03:51 pm
Germany's Bayer , which acquired seed company Monsanto this year, reduced its combined sales estimate for its most promising experimental drugs, acknowledging it needs to do more to replenish the development pipeline.
Read The Rest at
Danske investors bank on Maersk clan to chart...
OPEC works on deal to cut output, still needs...
You May Also Like
High-end residential sales witness better traction
'Mulan,' 'Harry Potter,' and Studio Ghibli -...
Potential Whistleblowers Against Kazakh...
Deals: AirPods fall back to $129, Apple Watch...
Germain Racing ponders 2021 plans, including...
Red Sox know PTBNLs in deadline deals, but...
Berlin / Germany
Sydney / Australia
All Rights Reserved
Powered By RSS-Script Light Version